The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.
暂无分享,去创建一个
H. Dombret | A. Plesa | C. Preudhomme | X. Thomas | O. Legrand | E. Cornet | J. Perrot | O. Wagner-Ballon | E. Raffoux | C. Pautas | J. Feuillard | J. Guy | P. Turlure | A. de Labarthe | J. Bastie | S. Castaigne | V. Salaun | E. Guérin | S. Chantepie | Florent Dumézy | Guillaume Olombel | F. Dumézy
[1] H. Dombret,et al. Final Analysis of the ALFA 0701 Study , 2014 .
[2] R. Hills,et al. A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m2 and 6mg/m2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial , 2014 .
[3] E. Estey,et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. , 2014, The Lancet. Oncology.
[4] G. Ehninger,et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia , 2014, Blood Cancer Journal.
[5] R. Larson,et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. , 2013, Blood.
[6] C. Craddock,et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] H. Dombret,et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study , 2012, The Lancet.
[8] I. Bernstein,et al. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. , 2008, Blood.
[9] C. Volteau,et al. Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study , 2011 .
[10] R. Foà,et al. High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation , 2011, Haematologica.
[11] R. Hills,et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] U. Mony,et al. Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia , 2010, Leukemia.
[13] P. Chevallier,et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] I. Bernstein,et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. , 2007, Blood.
[15] Bruce Greig,et al. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia , 2007, Cytometry. Part B, Clinical cytometry.
[16] Jonathan A. Cooper,et al. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. , 2004, Blood.
[17] V. Deneys,et al. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome , 2003, Leukemia.
[18] I. Bernstein,et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] F. Lanza,et al. CD34+/CD33+ blast cells: correlation with FAB subtypes. , 1995, Leukemia & lymphoma.
[20] P. Hokland,et al. Monoclonal antibodies in myeloid diseases: prognostic use in acute myeloid leukaemia. , 1991, Leukemia research.